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This BMJ Rapid Recommendation
article is one of a series that
provides clinicians with trustworthy
recommendations for potentially
practice changing evidence.
BMJ Rapid Recommendations
represent a collaborative effort
between the MAGIC group (http://
magicproject.org/) and The
BMJ. A summary is offered here
and the full version including
decision aids is on the MAGICapp
(https://app.magicapp.org), for all
devices in multilayered formats.
Those reading and using these
recommendations should consider
individual patient circumstances,
and their values and preferences
and may want to use consultation
decision aids in MAGICapp to
facilitate shared decision making
with patients. We encourage
adaptation and contextualisation
of our recommendations to local or
other contexts. Those considering
use or adaptation of content may
go to MAGICapp to link or extract
its content or contact The BMJ for
permission to reuse content in this
article.

Do corticosteroids reduce death or improve
recovery in people with sepsis or septic shock?
Our panel make a weak recommendation to
give corticosteroids to people with all types
and severity of sepsis, based on new evidence.
Because we are not certain that they are
beneficial, it is also reasonable not to prescribe
them. Patients’ values and preferences may guide
this decision-making process.
This rapid recommendation was triggered by two
trials, with differing conclusions whose results might
change practice:
•   ADRENAL (3658 patients who had septic shock)
found no statistically significant difference in 90
day mortality between the hydrocortisone and
placebo groups.1
•   APROCCHSS (1241 patients who had septic
shock) found that hydrocortisone plus
fludrocortisone reduced 90 day mortality.2
The trials are incorporated into a linked systematic review comparing corticosteroids with placebo.3 This BMJ Rapid Recommendation promptly
and transparently translates this evidence using
GRADE methodology for trustworthy guidelines.
Sepsis is a life threatening organ dysfunction from
infection. Currently most guidelines advise against

WHAT YOU NEED TO KNOW
•   Sepsis is a syndrome of life threatening

•
•

•

•

infection with organ dysfunction, and most
guidelines do not advise use of corticosteroids
to treat it in the absence of refractory shock
  Two new trials of corticosteroid treatment for
sepsis came to differing conclusions
  Corticosteroids may reduce the risk of
death by a small amount and increase
neuromuscular weakness by a small amount,
but the evidence is not definitive
  This guideline makes a weak recommendation
for corticosteroids in patients with sepsis;
both steroids and no steroids are reasonable
management options
  Fully informed patients who value avoiding
death over quality of life and function would
likely choose corticosteroids
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giving corticosteroids in sepsis in the absence of
refractory shock, but these guidelines have not taken
into account the new evidence. We do not anticipate
that new clinical trials will substantively alter the
evidence suggesting a small but uncertain mortality
reduction. The box below shows publications linked
in this Rapid Recommendation package. The main
infographic provides an overview of the absolute
benefits and harms. The table at the end of the article shows any evidence that has emerged since the
publication of this guideline.

Current understanding
Sepsis is life threatening organ dysfunction caused by a
dysregulated host response to infection.4 In practice, a
sepsis-related organ failure assessment (SOFA) score of
≥2 in patients with infections is sepsis (table 1).4 5 Worldwide, about 30 million people are hospitalised with sepsis every year and up to six million of them die.6
Clinicians typically manage sepsis with early, broad
spectrum antibiotics. They may provide supportive
treatment such as vasoactive drugs and mechanical ventilation. They track and adjust treatment based on clinical signs and laboratory data.7 Septic shock is the most
severe form of sepsis. These patients experience profound
circulatory, metabolic, and cellular abnormalities.4 8 They
require vasopressors to maintain perfusion pressure and
have elevated serum lactate concentrations despite adequate fluid repletion.
Linked articles in the BMJ Rapid Recommendation cluster
• Lamontagne F, Rochwerg B, Lytvyn L, et al. Corticosteroid
therapy for sepsis: a clinical practice guideline. BMJ
2018;362:k3284
––Summary of the results from the Rapid
Recommendation process
• Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al.
Corticosteroids in sepsis: an updated systematic review
and meta-analysis. Crit Care Med 2018. doi:10.1097/
CCM.00000000000032623
––Review and meta-analysis of all available randomised
trials that assessed corticosteroid therapy for sepsis
• MAGICapp (https://app.magicapp.org/public/guideline/
EZ1w8n)
––Expanded version of the results with multilayered
recommendations, evidence summaries, and decision
aids for use on all devices
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Population
Recommendation applies to:

People
with sepsis

Adults and children

Intra abdominal
infections

Any infectious source

Pneumonia

Patients with and without shock

SOFA score
of at least 2

Recommendation does not apply to:
Patients with pre-existing adrenal insufficiency
Non-infectious causes of shock
Neonates

Pregnant women

Anaphylactic
Cardiogenic
Hypovolaemic

Comparison
Corticosteroid
therapy
Intravenous
corticosteroids
plus usual care

CCS

or

Usual
care

+

No
corticosteroid
therapy

Corticosteroids

Strong

Usual
care

Usual care only

No corticosteroids

Weak

Weak

Strong

We suggest corticosteroid therapy rather than no corticosteroid therapy.
Either option is reasonable.

Comparison of benefits and harms
Favours corticosteroids

Mortality
Neuromuscular weakness

236
303

No important difference
Events per 1000 people
18 fewer
53 fewer
Unknown

Quality of Life

Favours no corticosteroids

254
250

Evidence quality
Low
Low
None

Stroke

10

No important difference

5

Very low

Myocardial infarction

27

No important difference

30

Very Low

13.1
32.0

Moderate
Moderate

Length of ICU stay
Length of hospital stay

12.4
31.3

Mean number of days
0.7 fewer
0.7 fewer

Key practical issues
Corticosteroids

No corticosteroids

Infusion or intermittent bolus dosing
Monitoring for serum sodium, potassium, and glucose

No key practical issues

Preferences and values
Those who place more value on
avoiding functional deterioration
and maximising quality of life than
on avoiding death may be more
likely to choose not to use
corticosteroids

Risk of death
Patients at greatest risk of death
(e.gs. those with shock, high
qSOFA/SOFA scores) will probably
have the greatest reduction in risk
of death with corticosteroids

Choice of corticosteroid
There are no clear differences in
efficacy or adverse effects between
different corticosteroids or
corticosteroid combinations. Most
studies used hydrocortisone

Disclaimer: This infographic is not a clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility
for any aspect of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions:
http://www.bmj.com/company/legal-information/
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System or organ and
measure

SOFA score
0
1

2

3

4

Respiratory:
PaO2/FiO2, mm Hg

≥400

200-299

100-199 with
respiratory support

<100 with
respiratory
support

50-99

20-49

<20

300-399

Coagulation:
Platelets, × 103/μL
≥150
100-149
Liver:
Bilirubin, μmol/L (mg/dL) <20 (1.2) 20-32 (1.2-1.9)
Circulatory:
Mean arterial pressure,
≥70
<70
mm Hg
Central nervous system:
Glasgow Coma Scale
score
Renal:
Creatinine, μmol/L
(mg/dL)
Urine output, mL/day

33-101 (2.0-5.9) 102-204 (6.0-11.9) >204 (12.0)
Low dose
dopamine
or any dose
dobutamine

Low-medium dose
noradrenalin or
adrenalin; medium
dose dopamine

High dose
noradrenalin,
adrenalin, or
dopamine

15

13-14

10-12

6-9

<6

<110
(1.2)
–

110-170 (1.21.9)
–

171-299 (2.03.4)
–

300-440 (3.5-4.9)

>440 (5.0)

<500

<200

*Our recommendation applies to patients with an infection and a SOFA score of ≥2.
PaO2 = partial pressure of oxygen (arterial). FiO2 = fraction of inspired oxygen.

Table 2 | Current recommendations for corticosteroid therapy in patients with sepsis
Society

Recommendation regarding corticosteroid use
In sepsis
In septic shock

“Surviving Sepsis” Against
for SCCM and
ESICM, 20167
Against
CIRCI guidelines
for SCCM and
12 13
ESICM, 2018
CAEP, 200814

NICE, 201715
JSICM, 201816

In favour for hypotension
refractory to fluid resuscitation
and vasopressor
In favour for shock not responsive
to fluid and at least moderate
dose vasopressor

In favour for haemodynamically
unstable patients not responsive
to fluid resuscitation and
vasopressor
Not mentioned Not mentioned
Against
In favour for shock not responsive
to initial fluid resuscitation and
vasoactive drugs

Other situations
History of adrenal insufficiency or
corticosteroid use

Acute respiratory distress syndrome
Community acquired pneumonia
Bacterial meningitis
History of adrenal insufficiency or
corticosteroid use

Against

Not mentioned

SCCM = Society of Critical Care Medicine. ESICM = European Society for Intensive Care Medicine. CIRCI = critical illness-related
corticosteroid insufficiency. CAEP = Canadian Association of Emergency Physicians. NICE = National Institute for Health and
Care Excellence (UK). JSICM = Japanese Society for Intensive Care Medicine.

It is possible that corticosteroids help improve the dysregulated immune response caused by sepsis9 and increase
blood pressure if it is low.10 Some clinicians have found this
biological rationale, and results of early studies, compelling. Others disagree and do not use corticosteroids.11
Most professional organisations recommend against
corticosteroid use in the absence of refractory shock.12
Table 2 summarises current professional society guidelines.

The evidence
The linked systematic review identified 42 randomised
controlled trials (RCTs) comparing corticosteroids with
no corticosteroids (typically placebo).3 Figure 2 provides
an overview of the trials and participants.
The systematic review includes total of 10 194 patients
who had sepsis. Of the 42 trials included, 24 restricted
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

enrolment to patients who had septic shock. The typical
patient was critically ill—a median of 32% of participants
died within the first month. The most common sources
of sepsis were pulmonary infections (median 44%) and
abdominal infections (median 17%). Most of the RCTs
used hydrocortisone alone (n=26), others used hydrocortisone plus fludrocortisone (n=2), methylprednisolone
(n=6), prednisolone (n=3), or dexamethasone (n=3)
(see fig 2). Although most of the clinical trials included
patients who had septic shock, many included patients
who did not (16 trials, 2241 patients). The linked systematic review provides detailed trial descriptions, including
risk of bias assessments and patient characteristics.3

Subgroups of patients
Corticosteroids did not seem to be more or less effective
in particular clinical subgroups, for example:
•   Septic shock
•   Pneumonia
•   Acute respiratory distress syndrome (ARDS)
•   Higher baseline risk of death
•   Different corticosteroid drugs (such as
hydrocortisone, methylprednisolone)
•   Different corticosteroid doses
•   Different corticosteroid regimens (such as single
agents or corticosteroid combinations such as
hydrocortisone plus fludrocortisone)
•   More recent v older trials
•   Trials with higher v lower risk of bias.
Older studies tended to use much higher doses of corticosteroids for a shorter time than are typically used now;
the pooled evidence from these older studies is imprecise
(few events), and the linked meta-analysis was underpowered to detect important subgroup differences such
as by dose. All tests for relative subgroup effects may
be underpowered to detect true differences because the
effect sizes are small, especially for mortality. Therefore,
we cannot be certain that a true subgroup effect does not
exist. Future meta-analyses of individual patient data
may help to identify populations that benefit more or
less from corticosteroids. Until such time, we can only
conclude that the evidence applies to all subgroups.
Understanding the recommendation
The main infographic provides an overview including the
benefits and harms, and our certainty in the evidence for
each outcome.
Absolute benefits and harms
There was better survival in the group taking corticosteroids, but this was not certain. This drives the weak rather
than strong recommendation.
Mortality
Corticosteroids may reduce mortality in the first month
after admission to an intensive care unit (ICU) by approximately 2%. However, the panel had low certainty that
this is true. The confidence interval crosses the line of no
difference, and the results were inconsistent, with some
RCTs showing a mortality reduction and others showing
none.
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Table 1 | Sepsis-related organ failure assessment (SOFA) score to help diagnose sepsis (adapted
from Vincent et al5)*
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The effect on longer term mortality (from 60 days to 1
year) was similar. Fewer studies reported this outcome,
so, although the results were consistent in the RCTs that
did report this outcome, the panel also had low certainty
that corticosteroids reduce longer term mortality.

Quality of life
No RCT reported quality of life outcomes at any time
point. The ADRENAL study investigators are collecting
quality of life data at six months, but these data have not
been published.17
Outcomes of some interest
Corticosteroids may reduce the length of ICU and hospital
stay by less than a day each (moderate quality evidence).
The impact of corticosteroids on other patient-important
outcomes such as stroke and myocardial infarction was
extremely uncertain. They may increase the risk of neuromuscular weakness by a small amount (low quality evidence
from seven RCTs). Possible explanations include the toxic
effects on nerve and muscle cells, and hyperglycaemia from
corticosteroid use.18 Weakness may compromise patients’
ability to function independently19 and delay recovery.20
In two of the seven RCTs evaluating weakness, it was
prospectively evaluated one month after enrolment.2 21
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Evaluations of neuromuscular weakness, especially in
RCTs that relied on investigator identification, were unreliable. The panel therefore believed that the RCTs probably underestimated the risk of neuromuscular weakness.

Outcomes of less importance
Corticosteroids probably increase the risk of hyperglycaemia and hypernatraemia. Corticosteroids probably
improve organ function at day 7 and the chance of shock
reversal at day 7.
Patient subgroups
Our recommendation applies to all patients with sepsis.
There was no meaningful difference in the efficacy of
corticosteroids in different groups of patients including
those with septic shock, pneumonia, acute respiratory
distress syndrome, or other sources of sepsis, or those
who were sicker. However, the absolute reduction in
mortality from corticosteroids will be greater in patients
with a higher risk of death. The absolute harm (such as
neuromuscular weakness) will also be greater in sicker
patients.
The analysis of a subgroup effect showed no convincing
evidence of such an effect. Based on published criteria for
credible subgroup effects,22 in the absence of a subgroup
4 of 8
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Fig 2 | Characteristics of patients and trials included in systematic review of the use of corticosteroids for treating sepsis3
CAP = community acquired pneumonia. ARDS = acute respiratory distress syndrome.

R A P I D R E C O M M E N DAT I O N S

effect, the interpretation of the effect of corticosteroids in
any particular subgroup should be guided by the effect in
the overall population of septic patients.
Several trials of corticosteroids for pneumonia or acute
respiratory distress syndrome have enrolled patients
who did not have sepsis; we did not consider these trials. Therefore, clinicians treating these conditions should
also consider evidence23 24 and guidelines12 applicable
to patients who have pneumonia and acute respiratory
distress syndrome.

Patient values and preferences
Fully informed patients who place a higher value on
avoiding death than on quality of life and function
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

would be more likely to choose to receive corticosteroids.
We heard from our patient partners that most patients
will want to reduce their risk of death, even if this reduction is small and uncertain. This view is consistent with
the experiences of the rest of the panel. Most patients
will likely be willing to accept a small increased risk of
weakness.
Patients (or their care givers and surrogate decisionmakers) will probably vary in how they would weigh
the balance of expected desirable and undesirable consequences from corticosteroids. We assume that most
patients want to avoid death and will value even a small,
uncertain reduction in mortality. We judge that they will
be less concerned about the possible increase in weakness among survivors. There is also likely to be a sizeable
minority of patients who would place a large value on
avoiding a very uncertain but possible decline in quality
of life and functional abilities even at the cost of a small
increase in risk of death.25 Shared decision making conversations about specific interventions in patients with
sepsis may not always be feasible, and could delay care.
However, clinicians should do their best to elicit each
patient's values and preferences. For example, they could
talk about the patient’s goals of care with the patient,
their family, and friends.

Practical considerations
Figure 3 outlines the key practical issues for patients
and clinicians discussing corticosteroid treatment for
sepsis.
The optimal corticosteroid drug, dose, and duration
of treatment are uncertain. Hydrocortisone was the
most commonly used corticosteroid in the RCTs and is
therefore a reasonable choice. Differences among corticosteroids, if they do exist, are probably small; dexamethasone, methylprednisolone, and prednisolone
were also studied and produced similar results. Adding
an agent that has additional mineralocorticoid activity,
such as fludrocortisone, could be helpful, but that is
highly speculative.
The typical hydrocortisone dose for an adult in the
RCTs was 200-300 mg/day, given either as an infusion
or as boluses every six hours.26 If an infusion is chosen,
a bolus of 50-100 mg can be given before the infusion.
In the RCTs the duration of treatment was typically 7-14
days, or less for those who were rapidly improving.
Inflammation may recur after discontinuing corticosteroid therapy,27 especially when it is stopped abruptly.28
Clinicians should carefully monitor all patients after discontinuing corticosteroids. In patients who deteriorate
after stopping corticosteroids (such as development of
shock or need for mechanical ventilation), reinitiating
corticosteroid therapy could be helpful, although this
is highly speculative. Whether corticosteroids should be
tapered rather than stopped abruptly is unclear. Corticosteroid induced adrenal suppression is probably duration
dependent, and so patients who receive longer courses of
corticosteroids (such as >14 days) might be particularly
likely to benefit from a taper before discontinuing and an
evaluation of hypothalamo-pituitary-adrenal axis function if in doubt.12
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HOW THIS RECOMMENDATION WAS CREATED
Our international panel included sepsis survivors, family
caregivers of patients who had sepsis, intensivists, internists,
nurses, an endocrinologist, physiotherapists, trialists, and
methodologists (see appendix 1 on bmj.com). They decided
on the scope of the recommendation and the outcomes that
are most important to patients. The panel judged death and
quality of life to be the most important outcomes. Myocardial
infarction, stroke, duration of stay in hospital and in the
intensive care unit (ICU), superinfections, and neuromuscular
weakness (such as ICU-acquired weakness) were also
identified as important outcomes for patients.
Surrogate outcomes such as time to shock reversal,
organ dysfunction measured by the sepsis-related organ
failure assessment (SOFA) score, hyperglycaemia, and
hypernatraemia were less important to the panel. This view
is consistent with GRADE recommendations to focus on
patient-important outcomes rather than surrogates.29
Subgroups of interest—The panel wanted to know whether
the effect of corticosteroids differed in people with sepsis,
compared with people who had septic shock, pneumonia,
acute respiratory distress syndrome, or were at higher risk
of death.3 30 They also wanted to know whether the type of
corticosteroid or its dose influenced outcomes.
The panel met by videoconference to discuss the evidence
and formulate a recommendation. No panel member had
financial conflicts of interest; intellectual and professional
conflicts were minimised and managed (see appendix 2 on
bmj.com).
The panel requested a systematic review of randomised
controlled trials on the impact of corticosteroid therapy for
patients who have sepsis, including those who have septic
shock.3 This review examines the two latest, as well as
previous studies, on corticosteroids in sepsis. The aim was
to resolve apparently conflicting evidence.
The panel followed the BMJ Rapid Recommendations
procedures for creating a trustworthy recommendation,31
including using the GRADE approach to critically appraise
the evidence and create recommendations (see appendix
3 on bmj.com).32 The panel considered the balance of
benefits, harms, and burdens of corticosteroids, the quality
of the evidence for each outcome, expected variations
in patient values and preferences, and acceptability
of corticosteroids.33 Determining patient values and
preferences occurred before the panel received the results of
the meta-analysis to reduce the risk that opinions regarding
outcome importance will be data driven. According to the
GRADE approach, recommendations can be strong or weak
and for or against a course of action.33 High quality evidence
of an effect on surrogate outcomes do not trigger strong
recommendations.

R A P I D R E C O M M E N DAT I O N S

Costs
Corticosteroids are typically inexpensive and widely
available. The impact of corticosteroids on the overall
costs to patients and to health systems is uncertain and
would be driven mostly by ICU and hospital lengths of
stay or prolonged periods of rehabilitation.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Future research
With the exception of the awaited analysis of quality of
life in the ADRENAL trial, there are currently no planned
or ongoing RCTs in patients who have sepsis that are likely
to substantively change the overall effect estimates for the
key outcomes. Given remaining uncertainty regarding the
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Fig 3 | Practical issues about use of corticosteroids for treatment of sepsis
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New evidence which has emerged after initial publication
Findings

Implications for recommendation(s)

effect of corticosteroids in different subgroups, additional
analyses of existing data to explore heterogeneity of treatment effects are logical next steps before more patients
are enrolled in similar trials. Such work mandates individual patient-data meta-analyses that rely on investigators sharing the data from their RCTs and cooperation
among research networks.
It is possible that additional adaptive RCTs could help
to resolve remaining uncertainty. Key research questions
to inform decision makers and future guidelines are:
•   What is the impact of corticosteroid therapy on
quality of life in the short and long term?
•   What is the impact of corticosteroid therapy on
functional recovery?
•   What is the impact of corticosteroid therapy on
healthcare costs?
•   Are there subgroups of patients with sepsis who
benefit more or less from corticosteroid therapy?
•   Are there differences between bolus and infusion
dosing?
•   Does the addition of fludrocortisone improve outcomes?

Updates to this article
The final table shows evidence that has emerged since
the publication of this article. As new evidence is published, a group will assess the new evidence and make
a judgment on to what extent it is expected to alter the
recommendation.
Competing interests: All authors have completed the BMJ Rapid
Recommendations interests disclosure form, and a detailed description of
all disclosures is reported in appendix 2 on bmj.com. As with all BMJ Rapid
Recommendations, the executive team and The BMJ judged that no panel
member had any financial conflict of interest. Professional and academic
interests are minimised as much as possible, while maintaining necessary
expertise on the panel to make fully informed decisions.
Funding: This guideline was not funded.
Transparency: R A C Siemieniuk affirms that the manuscript is an honest,
accurate, and transparent account of the recommendation being reported;
that no important aspects of the recommendation have been omitted;
and that any discrepancies from the recommendation as planned (and, if
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